中國巨石(600176.SH):巨石埃及擬投建年產12萬噸玻璃纖維池窯拉絲生產線
格隆匯8月17日丨中國巨石(600176.SH)公佈,公司全資子公司巨石集團有限公司之控股子公司巨石埃及擬在現有土地上投資建設一條年產12萬噸玻璃纖維池窯拉絲生產線,並擴建原材料加工設施,項目總投資3.35億美元。
通過項目的實施,將進一步優化公司產品結構,更好地滿足歐洲、中東、北美等地高端市場需要,對公司持續優化產品結構,提升盈利能力,增強核心競爭力,實現持續健康發展具有重要意義。
項目建成後,預計每年可實現銷售收入1.15億美元,年平均利潤總額4984.11萬美元(數據僅為公司對項目投資收益的預計金額,不構成公司對項目投資收益的承諾)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.